not surprisingly, Gilead's licensing program broke even in 2009, and by 2010 it had generated a $5 million surplus and reached more 1.4 million patients in low-income countries. in addition, Gilead has helped to create an ecosystem that will aid these countries as they produce and distribute other essential drugs.